We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » SUPREME COURT REFUSES TO HEAR PAXIL APPEAL

SUPREME COURT REFUSES TO HEAR PAXIL APPEAL

June 20, 2006

The U.S. Supreme Court has rejected a request by GlaxoSmithKline (GSK) to review an appeals court ruling allowing Apotex to market a generic version of GSK's antidepressant Paxil.

GSK appealed a decision by the U.S. Circuit Court of Appeals that ruled that GSK's patent on Paxil (paroxetine HCl) was invalid because another company discovered the drug accidentally several years earlier. In May, the Department of Justice filed a brief advising the court not to hear the case. "As the court of appeals correctly held, petitioners are not entitled to such a patent," U.S. Solicitor General Paul Clement said in the brief.

A spokeswoman for GSK said the company was disappointed with the Supreme Court's decision. While GSK would not have gained financially from a Supreme Court review as generic Paxil is already on the market, "We felt like it was an important issue to be considered," she said.

Richard Samp, chief counsel for the Washington Legal Foundation (WLF), said the decision would cause a "net decrease in research and development expenditures for new lifesaving therapies."

WLF said the appeals court's ruling "invalidated a significant pharmaceutical patent based on a finding that the drug was not 'novel' when the patent application was filed in 1986 -- even though it is undisputed that if the drug existed before then, it was in such minute quantities as to be undetectable." WLF also said that "by invalidating a major patent based on a position that conflicts with long-settled patent law precedents, the Federal Circuit is saying it is unwilling to uphold intellectual property rights in the face of public demands for lower drug prices."

The case is SmithKline Beecham v. Apotex, No. 05-489. (http://www.fdanews.com/did/5_120/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

  • Purple_Approved_Stamp.gif

    Seno Medical Gets Premarket Approval for Breast Cancer Diagnostic

  • Triple Vaccine, needles

    Moderna to Start New Trial Adding Third Shot of COVID-19 Vaccine

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing